"By Megan Brooks
Medscape Medical News
The US Food and Drug Administration (FDA) will require makers of prescription testosterone products to clarify the approved uses of these medications on the product label and add information"...
Because thrombolytic therapy increases the risk of bleeding, Retavase® (reteplase) is contraindicated in the following situations:
- Active internal bleeding
- History of cerebrovascular accident
- Recent intracranial or intraspinal
- Intracranial neoplasm, arteriovenous
- Known bleeding diathesis
- Severe uncontrolled hypertension
Last reviewed on RxList: 9/15/2008
Additional Retavase Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.